Patents by Inventor Christopher P Rusconi
Christopher P Rusconi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8859518Abstract: The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acid ligands to provide ideal modulators of coagulation. These improved nucleic acid ligands and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass.Type: GrantFiled: January 28, 2013Date of Patent: October 14, 2014Assignee: Regado Biosciences, Inc.Inventor: Christopher P Rusconi
-
Publication number: 20140275225Abstract: The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.Type: ApplicationFiled: October 8, 2013Publication date: September 18, 2014Applicant: DUKE UNIVERSITYInventors: BRUCE A. SULLENGER, CHRISTOPHER P. RUSCONI
-
Publication number: 20140128454Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.Type: ApplicationFiled: November 7, 2012Publication date: May 8, 2014Applicant: REGADO BIOSCIENCES, INC.Inventors: Juliana M. Layzer, Christopher P. Rusconi, Douglas Brooks, Steven Zelenkofske
-
Publication number: 20140128587Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.Type: ApplicationFiled: November 7, 2012Publication date: May 8, 2014Applicant: REGADO BIOSCIENCES, INC.Inventors: Juliana M. Layzer, Christopher P. Rusconi, Douglas Brooks, Steven Zelenkofske
-
Patent number: 8586524Abstract: The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.Type: GrantFiled: April 26, 2007Date of Patent: November 19, 2013Assignee: Duke UniversityInventors: Bruce A. Sullenger, Christopher P Rusconi
-
Publication number: 20130197065Abstract: The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acid ligands to provide ideal modulators of coagulation. These improved nucleic acid ligands and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass.Type: ApplicationFiled: January 28, 2013Publication date: August 1, 2013Applicant: Regado Biosciences, Inc.Inventor: Christopher P. Rusconi
-
Patent number: 8367627Abstract: Focused aptamer libraries are constructed in accordance with a proteome (i.e., complex mixture of native biomolecules). The libraries may be screened to identify one or more candidate aptamers with desired biological activities other than specific binding to a target. Aptamers which are selected or derivatives thereof may be used for those specific activities in biological systems. Any combination of deconvoluting a focused library (functional profiling), increasing frequencies of particular aptamers in a focused library (Laser SELEX), and decreasing frequencies of particular aptamers in a focused library (DeSELEX) may be performed prior to assaying biological activity.Type: GrantFiled: September 15, 2006Date of Patent: February 5, 2013Assignee: Duke UniversityInventors: Bruce A. Sullenger, Juliana M. Layzer, Christopher P. Rusconi, Sabah Oney, Nanette L. S. Que-Gewirth
-
Patent number: 8318923Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.Type: GrantFiled: June 3, 2010Date of Patent: November 27, 2012Assignee: Regado Biosciences, Inc.Inventors: Juliana M. Layzer, Christopher P. Rusconi, Douglas Brooks, Steven L. Zelenkofske
-
Publication number: 20120277419Abstract: A method for preparing a therapeutic pegylated oligonucleotide is described. The method involves synthesis, cleavage and purification steps designed to improve the efficiency whereby the therapeutic oligonucleotide may be prepared. Also described are methods for large scale preparation at the improved efficiency.Type: ApplicationFiled: April 26, 2012Publication date: November 1, 2012Inventors: DOUGLAS BROOKS, CHRISTOPHER P. RUSCONI
-
Patent number: 8283330Abstract: The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.Type: GrantFiled: December 14, 2009Date of Patent: October 9, 2012Assignee: Duke UniversityInventors: Bruce A. Sullenger, Christopher P Rusconi
-
Publication number: 20120178917Abstract: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.Type: ApplicationFiled: March 23, 2012Publication date: July 12, 2012Applicant: DUKE UNIVERSITYInventors: BRUCE A. SULLENGER, Christopher P. Rusconi
-
Publication number: 20120095085Abstract: Provided are ligands which bind to and regulate the function of CLEC-2. Nucleic acid CLEC-2 ligands described herein are able to inhibit CLEC-2 mediated platelet aggregation and may also provide use in regulating CLEC-2-mediated processes such as thrombus formation, tumor metastasis, lymphangiogenesis, HIV dissemination, inflammatory response, cytokine production and phagocytosis. Also disclosed herein are modulator molecules which can reverse the activity of the CLEC-2 ligand both in vitro and in vivo and ex vivo.Type: ApplicationFiled: October 14, 2011Publication date: April 19, 2012Inventors: JULIANA M. LAYZER, Sanjoy K. Mahanty, Samuel C. Wolff, Catherine C. Redick, Christopher P. Rusconi
-
Patent number: 8143233Abstract: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.Type: GrantFiled: December 17, 2010Date of Patent: March 27, 2012Assignee: Duke UniversityInventors: Bruce A. Sullenger, Christopher P. Rusconi
-
Publication number: 20110160443Abstract: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.Type: ApplicationFiled: December 17, 2010Publication date: June 30, 2011Inventors: Bruce A. Sullenger, Christopher P. Rusconi
-
Patent number: 7858591Abstract: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.Type: GrantFiled: October 26, 2007Date of Patent: December 28, 2010Assignee: Duke UniversityInventors: Bruce A. Sullenger, Christopher P. Rusconi
-
Publication number: 20100311820Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.Type: ApplicationFiled: June 3, 2010Publication date: December 9, 2010Applicant: Regado Biosciences, IncInventors: Juliana M. Layzer, Christopher P. Rusconi, Douglas Brooks, Steven L. Zelenkofske
-
Patent number: 7812001Abstract: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.Type: GrantFiled: October 26, 2007Date of Patent: October 12, 2010Assignee: Duke UniversityInventors: Bruce A. Sullenger, Christopher P. Rusconi
-
Publication number: 20100249217Abstract: The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.Type: ApplicationFiled: December 14, 2009Publication date: September 30, 2010Inventors: BRUCE A. SULLENGER, Christopher P. Rusconi
-
Patent number: 7776836Abstract: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.Type: GrantFiled: October 26, 2007Date of Patent: August 17, 2010Assignee: Duke UniversityInventors: Bruce A. Sullenger, Christopher P. Rusconi, Rebekah R. White
-
Patent number: 7776837Abstract: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.Type: GrantFiled: November 6, 2007Date of Patent: August 17, 2010Assignee: Duke UniversityInventors: Bruce A. Sullenger, Christopher P. Rusconi